Mechanisms of quinolone action and microbial response.

Over the years, chromosomal mapping of the bacterial genome of Escherichia coli has demonstrated that many loci are associated with quinolone resistance, which is mainly a result of chromosomal mutation or alteration of the quantity or type of porins in the outer membrane of Gram-negative bacteria. There has been one report of a small and confined episode of plasmid-mediated resistance to fluoroquinolones, which did not appear to persist. With the increasingly widespread use of an expanding range of fluoroquinolone antibiotics, a range and mix in individual bacterial isolates of the different mechanisms of resistance to fluoroquinolones will undoubtedly be encountered amongst clinically significant bacteria. Currently, transferable resistance is extremely rare and most resistant bacteria arise from clonal expansion of mutated strains. However, it is conceivable that in the future, horizontal gene transfer may become a more important means of conferring resistance to fluoroquinolones.

[1]  G. Jacoby,et al.  Prevalence of Plasmid-Mediated Quinolone Resistance , 2003, Antimicrobial Agents and Chemotherapy.

[2]  Satoshi Murakami,et al.  Crystal structure of bacterial multidrug efflux transporter AcrB , 2002, Nature.

[3]  J. Karlowsky,et al.  Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000. , 2002, International journal of antimicrobial agents.

[4]  L. Grinius,et al.  NorA Functions as a Multidrug Efflux Protein in both Cytoplasmic Membrane Vesicles and Reconstituted Proteoliposomes , 2002, Journal of bacteriology.

[5]  P. Rhomberg,et al.  Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995 , 2002, Antimicrobial Agents and Chemotherapy.

[6]  L. Piddock,et al.  Expression of Efflux Pump Gene pmrA in Fluoroquinolone-Resistant and -Susceptible Clinical Isolates of Streptococcus pneumoniae , 2002, Antimicrobial Agents and Chemotherapy.

[7]  K. Lewis,et al.  Biofilms and Planktonic Cells of Pseudomonas aeruginosa Have Similar Resistance to Killing by Antimicrobials , 2001, Journal of bacteriology.

[8]  F. Yoshimura,et al.  A MATE Family Multidrug Efflux Transporter Pumps out Fluoroquinolones in Bacteroides thetaiotaomicron , 2001, Antimicrobial Agents and Chemotherapy.

[9]  L. Fisher,et al.  Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis, Intracellular Levels, and Phenotypes of Wild-Type and Mutant Proteins , 2001, Antimicrobial Agents and Chemotherapy.

[10]  A. Drlica-Wagner,et al.  Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus aureus , 2001, Antimicrobial Agents and Chemotherapy.

[11]  Xilin Zhao,et al.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Venezia,et al.  Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. , 2001, The Journal of antimicrobial chemotherapy.

[13]  W. Yam,et al.  Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. , 2001, Emerging infectious diseases.

[14]  A. Dalhoff,et al.  Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Y. Onodera,et al.  Molecular Cloning of the gyrA andgyrB Genes of Bacteroides fragilis Encoding DNA Gyrase , 1999, Antimicrobial Agents and Chemotherapy.

[16]  J. Domagala,et al.  Fluoroquinolone Action against Clinical Isolates ofMycobacterium tuberculosis: Effects of a C-8 Methoxyl Group on Survival in Liquid Media and in Human Macrophages , 1999, Antimicrobial Agents and Chemotherapy.

[17]  M. Ferraro,et al.  Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parELoci , 1999, Antimicrobial Agents and Chemotherapy.

[18]  R. Wise,et al.  Identification of an Efflux Pump Gene,pmrA, Associated with Fluoroquinolone Resistance inStreptococcus pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[19]  J. Domagala,et al.  Fluoroquinolone Action against Mycobacteria: Effects of C-8 Substituents on Growth, Survival, and Resistance , 1998, Antimicrobial Agents and Chemotherapy.

[20]  A. Khodursky,et al.  The Mechanism of Inhibition of Topoisomerase IV by Quinolone Antibacterials* , 1998, The Journal of Biological Chemistry.

[21]  J. Domagala,et al.  Killing of Staphylococcus aureus by C-8-Methoxy Fluoroquinolones , 1998, Antimicrobial Agents and Chemotherapy.

[22]  G. Jacoby,et al.  Quinolone resistance from a transferable plasmid , 1998, The Lancet.

[23]  J. Domagala,et al.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Narita,et al.  Quinolone susceptibility of norA-disrupted Staphylococcus aureus , 1997, Antimicrobial agents and chemotherapy.

[25]  K. Drlica,et al.  DNA gyrase, topoisomerase IV, and the 4-quinolones , 1997, Microbiology and molecular biology reviews : MMBR.

[26]  H. Ito,et al.  Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus , 1997, Antimicrobial agents and chemotherapy.

[27]  J. Ruiz,et al.  The region of the parE gene, homologous to the quinolone-resistant determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates. , 1997, The Journal of antimicrobial chemotherapy.

[28]  J. Blondeau,et al.  Fluoroquinolone resistance: mechanisms and epidemiology. , 1997, Journal of medical microbiology.

[29]  L. Fisher,et al.  Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones , 1997, Antimicrobial agents and chemotherapy.

[30]  L. Fisher,et al.  NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations , 1996, Antimicrobial agents and chemotherapy.

[31]  M. Snyder,et al.  DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. , 1996, Journal of molecular biology.

[32]  A. Khodursky,et al.  Topoisomerase IV is a target of quinolones in Escherichia coli. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Kaatz,et al.  Inducible NorA-mediated multidrug resistance in Staphylococcus aureus , 1995, Antimicrobial agents and chemotherapy.

[34]  I. Morrissey,et al.  Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition , 1994, Antimicrobial Agents and Chemotherapy.

[35]  D. Livermore,et al.  Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin , 1994, Antimicrobial Agents and Chemotherapy.

[36]  K. Poole,et al.  Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon , 1993, Journal of bacteriology.

[37]  J. Hearst,et al.  Molecular cloning and characterization of acrA and acrE genes of Escherichia coli , 1993, Journal of bacteriology.

[38]  H. Niki,et al.  New topoisomerase essential for chromosome segregation in E. coli , 1990, Cell.

[39]  P. Heisig,et al.  Mechanisms of quinolone resistance , 2005, Infection.

[40]  L. McGee,et al.  Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. , 2002, The Journal of antimicrobial chemotherapy.

[41]  T. Fujiwara,et al.  Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus , 2001, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.